Semaglutide 7 mg: does this dose exist, and what does it mean for your treatment?

Why are people searching for "semaglutide 7 mg" in the first place?

It's a reasonable search to make. When Novo Nordisk announced the higher Wegovy dose in early 2026, early coverage shortened "7.2 mg" to "7 mg" fairly often, and that shorthand has stuck around in forums and social media. There's also genuine confusion between Wegovy and Rybelsus: both contain semaglutide, and Rybelsus does have a 7 mg tablet, but it is one step in a diabetes treatment schedule (3 mg, 7 mg, 14 mg), not a weight-loss dose. If you've been told you're on "semaglutide 7 mg" by a diabetes team, that's almost certainly Rybelsus, prescribed for blood-sugar management rather than weight reduction.

One misconception worth gently setting aside is that a higher number automatically means a more effective or faster treatment. The dose schedule for any GLP-1 medicine exists primarily to protect tolerability. Moving through the steps carefully tends to produce better long-term outcomes than rushing to the top.

The full Wegovy dose schedule (including where 7.2 mg sits) is covered clearly in our guide to Wegovy doses, and the broader picture of how semaglutide works for weight management is on the Wegovy treatment overview page.

What did the MHRA actually approve at 7.2 mg, and when?

On 14 April 2026, the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, one pre-set weekly injection, auto-dosing mechanism, built-in covered needle that locks after use. This followed an earlier approval in January 2026 of 7.2 mg delivered as three 2.4 mg pens per week, so the spring 2026 approval simply added a more convenient delivery format. The 7.2 mg dose is licensed for adults with a BMI of 30 or above; it is not currently approved for the BMI 27–29.9 plus comorbidity group or for the cardiovascular risk-reduction indication.

Trial data for the higher dose (published alongside the approval announcement) reported around 20.7% average weight loss over 72 weeks at 7.2 mg, narrowing the gap with tirzepatide 15 mg, which produced around 20–21% in the SURMOUNT-1 trial published in the New England Journal of Medicine. Both figures come from clinical trials under controlled conditions, and individual results vary considerably.

Starting dose remains 0.25 mg regardless of the target. The prescriber titrates upward through the schedule, and 7.2 mg is the ceiling, not an assumed destination for everyone.

How does the Wegovy dose schedule actually work in practice?

The licensed Wegovy schedule runs: 0.25 mg for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg as the previous standard maintenance dose, each step held for at least four weeks. With 7.2 mg now licensed, the full ladder extends to 7.2 mg for those who can tolerate it and who are assessed as likely to benefit from going higher. For context on the earlier rungs, the 0.25 mg to 1 mg transition is the phase where most GI side effects are felt, and the expected weight loss at 2.4 mg is worth understanding before thinking about whether to go further.

Side effects across the schedule are dominated by gastrointestinal symptoms: nausea, loose stools, constipation, indigestion, and burping are the most commonly reported. They tend to be most noticeable in the first week or two after a dose step, then settle. The NHS semaglutide medicines page lists the full side-effect profile; the Patient Information Leaflet in your pack covers it in detail for your specific product. Seek urgent medical attention for severe, persistent stomach pain that spreads to your back, this is the key symptom the MHRA flagged in its January 2026 Drug Safety Update on GLP-1 medicines and pancreatitis.

Every dose decision is made by a prescriber, not set in advance. There is no obligation to reach any particular step, and the semaglutide dosing overview explains how those clinical conversations tend to work.

Does this change how semaglutide compares to other weight-loss options?

It shifts the picture somewhat. When Wegovy's standard maintenance dose was 2.4 mg, the gap between semaglutide and tirzepatide (Mounjaro) in head-to-head evidence (the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025) showed tirzepatide producing greater average weight loss. At 7.2 mg, semaglutide's results are closer to the highest tirzepatide doses.

The practical question is always which medicine suits a specific person's health picture, not which number looks largest. Tirzepatide acts on two receptors (GIP and GLP-1); semaglutide acts on one. Both are injectable, once weekly. The oral Wegovy tablet (approved by the MHRA on 11 June 2026, the first oral GLP-1 for weight management licensed in the UK) adds a needle-free option for those who prefer it, more detail on that route is on the weight-loss treatments overview.

Cost is often part of this comparison too. Since Eli Lilly raised Mounjaro's list price in September 2025, private prices for both medicines have generally sat in a similar range depending on dose and provider. Our guide to Wegovy pricing sets out what a legitimate private prescription typically includes.

If you'd like a prescriber to look at your specific situation, you can start a free consultation with our clinical team. A GPhC-registered prescriber reads every application the same day.